The risk factor responsible for the death of a woman, if she carries a mutated BRCA1 gene based on the given study. Introduction: Cancer is a disease developed due to unlimited cell division. It is a genetic disease in which changes take place in the genes due to mutations. Some mutations are hereditary and the cancer caused due to this are called familial cancers and the other cancers that are non-hereditary are known as sporadic cancers.

Question

Describe error prone polymerases and the process of translesion synthesis (TLS). In regards to tumor biology, what is the mutator phenotype hypothesis? What are some ways in which error-prone polymerases could be targeted for potential anti-cancer treatments?

Answer 1

Question

Chapter 16, Problem 2ITD

Summary Introduction

To review:

The risk factor responsible for the death of a woman, if she carries a mutated BRCA1gene based on the given study.

Introduction:

Cancer is a disease developed due to unlimited cell division. It is a genetic disease in which changes take place in the genes due to mutations. Some mutations are hereditary and the cancer caused due to this are called familial cancers and the other cancers that are non-hereditary are known as sporadic cancers.

Expert Solution & Answer

Trending nowThis is a popular solution!

See solution

Check out sample textbook solution

Students have asked these similar questions

Describe error prone polymerases and the process of translesion synthesis (TLS). In regards to tumor biology, what is the mutator phenotype hypothesis? What are some ways in which error-prone polymerases could be targeted for potential anti-cancer treatments?

please help

In Demircioglu et al (2019), the authors found that promoter switching for the ERBB2 gene was often associated with mutations in other known oncogenes and tumor suppresor genes. However, they argued that promoter switching may be correlated with cancer development and progression regardless of additional mutations. What evidence did they have to support this idea ? O They found that patients who had ERBB2 promoter switching but no other mutations in known oncogenes (OG) and tumor suppressor genes (TSG) carried many other mutations in genes that may have contributed to cancer progression and had not been identified as OG or TSG yet. O They saw that patients that showed promoter switching but did not have any other identifiable mutations had poorer prognosis than patients without promoter switching This was actually a discussion point; the authors did not have any experimental evidence to support their claim. O They treated all patients that showed promoter switching with the same drug…